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BACKGROUND & AIMS: We evaluated the efﬁcacy and safety of
obeticholic acid (OCA, a-ethylchenodeoxycholic acid) in a ran-
domized controlled trial of patientswith primarybiliary cirrhosis
who had an inadequate response to ursodeoxycholic acid ther-
apy. METHODS: We performed a double-blind study of 165
patients with primary biliary cirrhosis (95% women) and levels
of alkaline phosphatase (ALP) 1.5- to 10-fold the upper limit of
normal. Patients were randomly assigned to groups given 10 mg,
25 mg, or 50 mg doses of OCA or placebo, once daily for 3
months. Patients maintained their existing dose of ursodeox-
ycholic acid throughout the study. The primary outcome was
change in level of ALP from baseline (day 0) until the end of the
study (day 85 or early termination). We also performed an open-
label extension of the trial in which 78 patients were enrolled and
61 completed the ﬁrst year. RESULTS: OCA was superior to
placebo in achieving the primary end point. Subjects given OCA
had statistically signiﬁcant relative reductions in mean ALP from
baseline to the end of the study (P < .0001 all OCA groups vs
placebo). Levels of ALP decreased 21%–25% on average from
baseline in the OCA groups and 3% in the placebo group. Sixty-
nine percent (68 of 99) of patients given OCA had at least a
20% reduction in ALP compared with 8% (3 of 37) of patients
given placebo (P < .0003). Among secondary end points, levels of
g-glutamyl transpeptidase decreased 48%–63%, on average,
among subjects given OCA, vs a 7% decrease in the group given
placebo; levels of alanine aminotransferase decreased 21%–35%
on average among subjects given OCA vs none of the patients
given placebo. Pruritus was the principal adverse event; inci-
dence values in the OCA 10 mg, 25 mg, and 50 mg groups were
47% (not signiﬁcantly different), 87% (P < .0003), and 80%
(P < .006), respectively, vs 50% in the placebo group. In the
extension study, levels of ALP continued to decrease to a meanlevel of 202 ± 11 U/L after 12 months vs 285 ± 15 U/L at
baseline. CONCLUSIONS: Daily doses of OCA, ranging from 10 to
50 mg, signiﬁcantly reduced levels of ALP, g-glutamyl trans-
peptidase, and alanine aminotransferase, compared with placebo,
in patients with primary biliary cirrhosis who had inadequate
responses to ursodeoxycholic acid. The incidence and severity of
pruritus were lowest among patients who received 10 mg/d OCA.
Biochemical responses to OCA were maintained in a 12-month
open-label extension trial. ClinicalTrials.gov ID: NCT00550862.
Keywords: Cholestasis; Bile Acids; FXR; Dose Study.
Watch this article’s video abstract and others at http://bit.ly/1q51BlW.Scan the quick response (QR) code to the left
with your mobile device to watch this article’s
video abstract and others. Don’t have a QR code
reader? Get one by searching ‘QR Scanner’ in
your mobile device’s app store.rimary biliary cirrhosis (PBC) is a chronic, progres-Psive autoimmune cholestatic liver disease that im-
pacts quality of life and is associated with increased
mortality.1 PBC is characterized by lymphocytic cholangitis
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ment of ﬁbrosis, cirrhosis, and liver failure. Consistent with
US and European guidelines, the current diagnosis of PBC is
typically made on the basis of elevated alkaline phosphatase
(ALP) values and positive anti-mitochondrial antibody reac-
tivity2 and, in keeping with this, the use of liver biopsy for
diagnosis and staging has decreased signiﬁcantly. PBC is
increasingly diagnosed at earlier stages.3–5 The only
approved drug to treat patients with PBC is ursodeoxycholic
acid (UDCA), a hydrophilic, noncytotoxic bile acid (BA) that is
widely used.1,6,7 However, up to 40% of UDCA-treated pa-
tients have an inadequate biochemical response, depending
on the criteria used, and such patients have signiﬁcantly
worse transplant-free survival rates than UDCA-responsive
patients.8–11 Accordingly, there is a signiﬁcant medical need
for new therapies for the treatment of PBC.12–19
Obeticholic acid (OCA, INT-747) is a semi-synthetic
analogue of the primary BA chenodeoxycholic acid
(CDCA), which selectively activates the nuclear hormone
receptor farnesoid X receptor (FXR).20,21 CDCA is the
endogenous FXR agonist; the 6-a ethyl substitution on OCA
imparts a nearly 100-fold greater FXR-activating potency.21
UDCA is an epimer of CDCA, but lacks meaningful FXR ac-
tivity. OCA has shown anti-cholestatic, anti-inﬂammatory,
and anti-ﬁbrotic effects mediated by FXR activation in pre-
clinical and clinical studies.20–23 Therefore, we reasoned
that a more potent FXR agonist would have a positive
impact in patients with PBC. In this article, we report ﬁnd-
ings from a 3-month, placebo-controlled, dose–response
trial of OCA added to UDCA in patients with PBC with an
inadequate UDCA response. We also report results from
patients on OCA treatment followed through 12 months in
an open-label extension trial.Materials and Methods
Patients
Patients, 18 to 75 years of age with PBC,24 on a stable dose of
UDCA for at least 6 months before screening, were enrolled. PBC
was diagnosed by at least 2 of the following: history of increased
ALP levels for at least 6 months; positive anti-mitochondrial
antibody titer (>1:40 titer on immunoﬂuorescence or M2 pos-
itive by enzyme-linked immunoabsorbant assay) or PBC-speciﬁc
antinuclear antibodies; or liver biopsy consistent with PBC.
Patients were required to have a mean baseline ALP value
between 1.5 and 10 the upper limit of normal range (ULN ¼
117 U/L for women; 129 U/L for men). Key exclusion criteria
were elevated plasma aspartate aminotransferase (AST) or
alanine aminotransferase (ALT) levels >5 ULN; bilirubin >2
ULN; serum creatinine >1.5 mg/dL (133 mmol/L); use of
colchicine, methotrexate, azathioprine, or systemic corticoste-
roids at any time during the 3 months before screening; and
history or presence of hepatic decompensation. Patients with
other concomitant liver diseases, including autoimmune hepa-
titis overlap, were also excluded. Patients maintained their
existing dose of UDCA throughout the study.
The study protocol and subsequent amendments were
reviewed and approved by the appropriate Ethics Committees
or Institutional Review Boards at each site. The trial waspreregistered (www.clinicaltrials.gov; NCT00550862 and
www.controlled-trials.com; ISRCTN67465025). The study pro-
tocol is available on request. All authors had access to complete
datasets. GMH, LA, CS, TB-J, EC, OB, and DS ﬁnalized analysis
and data presentation. GMH, LA, and DS had ﬁnal responsibility
to submit the manuscript after all authors reviewed and
approved the manuscript.
Sample Size
The study sample size was calculated in terms of effect size;
35 patients per group provided 80% power to detect an effect
size of 0.70, which translates to approximately a 10% mean
greater reduction in ALP levels between groups (see
Supplementary Table 1).
Randomization and Masking
Eligible patients were randomly assigned (1:1:1:1) to 1 of 4
treatment groups for 85 days (3 months): OCA 10 mg, OCA
25 mg, OCA 50 mg, or a matching placebo administered once
daily. The computerized randomization schedule used a block
size of 4 at each center.
Recruitment and the double-blind study phase occurred
between November 2007 and May 2009. Study assessment visits
were performed on days 0 (randomization), 15, 29, 57, and 85
(ie, 3 months or end of treatment). Patients had a follow-up visit
(off drug therapy) 14 days later. ALP and liver enzymes levels
were determined at each visit by a central laboratory. Safety
assessments included adverse events (AEs), pruritus, physical
examinations, vital signs, clinical laboratory testing including
lipids, and electrocardiograms. Blood samples for BAs, ﬁbroblast
growth factor-19 (FGF19), BA precursor C4 (7a-hydroxy-4-
cholesten-3-one) (C4), C-reactive protein, and IgM assays were
obtained at days 0 and 85 or at end of treatment, if earlier.
Open-label OCA therapy was offered to patients completing
the double-blind portion of the study at 13 centers. These pa-
tients were dosed for at least an additional 12 months (unless
they discontinued earlier). Patients were restarted on OCA
10-mg once-daily dosing or the dose assigned during the
double-blind phase and allowed to titrate up or down at the
discretion of the investigator based on individual ALP response
and tolerability. Mean daily OCA doses of <10 mg, typically to
manage pruritus, were achieved by alternate or every third day
dosing of a 10-mg tablet.
For the double-blind and open-label extension, pruritus was
managed with dose reduction, medication interruption, use of
other medications (eg, antihistamines or BA sequestrants), or
discontinuation, as deemed appropriate.
Primary Efﬁcacy End Point
The primary end point was the relative (percent) change in
ALP values from baseline (day 0) to end of study (day 85) in
each of the OCA groups compared with placebo in the modiﬁed
intent-to-treat (mITT) population.
Efﬁcacy Assessed by Published
Response Criteria
The proportion of patients meeting the various previously
published “nonresponse” criteria at the start of the study were
also evaluated (eg, Paris I,8 II,9 Toronto criteria25,26), in
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bilirubin levels.
Secondary End Points
Secondary and exploratory end points were evaluated in
the ITT population and included changes in other liver
enzymes (AST, ALT, g-glutamyl transferase [GGT]), conjugated
bilirubin, and albumin values expressed as both absolute
values, change from baseline, and proportional changes. Other
evaluations included assessment of lipids, free fatty acids,
C-reactive protein, and IgM. Changes were measured in blood
serum concentrations of total endogenous BAs and the indi-
vidual BAs: UDCA, CDCA, cholic acid, lithocholic acid, and
deoxycholic acid (DCA). Changes in C4 and FGF19, a marker of
FXR activation, were also assessed. Serum levels of unconju-
gated and glycine- or taurine-conjugated OCA and other BAs
were determined by liquid chromatography tandem mass
spectrometry.28 FGF19 concentrations were assayed using the
solid-phase enzyme-linked immunoabsorbant assay Quanti-
kine FGF19 Immunoassay (R&D Systems, Minneapolis, MN).
Serum C4 levels were determined by high-performance liquid
chromatography.29
Statistical Analysis
Three analysis populations were evaluated: an ITT popu-
lation (N ¼ 165) of randomized patients who received at least
one dose of OCA; an mITT population (N ¼ 161) of patients
who received at least one dose of OCA and had at least oneTable 1.Demographic and Baseline Characteristics of Primary
Characteristics Placebo (n ¼ 38) OCA, 10 m
Sex, n (%)
Male 2 (5) 0
Women 36 (95) 38
Age, y
Mean (SD) 54.8 (8.5) 55.6
Range 36.0–72.0 37.0–
Body weight, kg
Mean (SD) 74.3 (15.9) 73.6
Range 44.0–107.6 50.0–
Body mass index, kg/m2
Mean (SD) 27.4 (5.2) 27.8
Range 19.1-38.6 19.9–
Laboratory markers, mean (SD)
ALP, U/L 275.2 (102.7) 294.4
Bilirubin, mg/dL 0.2 (0.2) 0.2
Albumin, g/dL 4.2 (0.3) 4
Platelets, 103/mL 281 (106) 272
INR 1.00 (0.06) 1.01
PBC inclusion criteria, n (%)
History of increased ALP 37 (97) 36
Positive AMA titer 33 (87) 28
Liver biopsy 33 (87) 35
Total UDCA daily dose
at study entry, mg/kg
Mean (SD) 15.9 (4.4) 15.9
Range 8.8–26.9 7.2–
1st3rd quartile 13–17.8 13.5–
AMA, anti-mitochondrial antibody; INR, international normalizedpost-baseline ALP evaluation <7 days after their last dose of
OCA; and a completer population (N ¼ 136) of patients who
had completed 85 days of treatment were also deﬁned.
A hierarchical testing strategy30 was used to account for
multiple comparisons; statistical signiﬁcance was evaluated at
a ¼ .05 for 10 mg vs placebo, at a ¼ .05 for 25 mg vs placebo,
then at a ¼ .05 for 50 mg vs placebo. The last observation
carried forward method was used for missing data
(Supplementary Table 2). Primary analyses were performed on
the mITT population. All secondary analyses were performed
on the ITT dataset only. Additional ALP evaluations over time
were analyzed for the completer population. Pair-wise com-
parisons for OCA treatment groups vs placebo changes used
the 2-sided Wilcoxon Mann-Whitney test at a 5% signiﬁcance
level. Safety variables were summarized by treatment
group with descriptive statistics. Disease severity criteria
were assessed by Fisher’s exact test and the response analysis
by c2 test.Results
Study Patients
One hundred and sixty-ﬁve patients from 41 North
American and European centers were randomized in a
1:1:1:1 fashion to placebo or 1 of 3 once-daily doses of OCA,
10mg, 25mg, and 50mg (Supplementary Figure 1 for patient
disposition). Nearly all enrolled patients werewomen (95%),
Caucasian (96%), and had a positive anti-mitochondrialBiliary Cirrhosis Patients
g (n ¼ 38) OCA, 25 mg (n ¼ 48) OCA, 50 mg (n ¼ 41)
(0) 3 (6) 3 (7)
(100) 45 (94) 38 (93)
(9.3) 55.9 (8.0) 54.0 (9.7)
71.0 35.0–69.0 37.0–71.0
(13.6) 72.7 (13.4) 70.9 (17.1)
99.2 45.4–101.3 46.2–116.0
(4.7) 27.4 (5.1) 26.4 (6.2)
37.5 18.9–39.6 17.6–45.3
(149.4) 290.0 (123.6) 286.9 (106.2)
(0.2) 0.2 (0.1) 0.3 (0.2)
(0.5) 4.1 (0.4) 4.2 (0.3)
(96) 275 (92) 244 (92)
(0.07) 1.02 (0.13) 1.05 (0.27)
(95) 46 (96) 39 (95)
(74) 40 (83) 33 (80)
(92) 43 (90) 34 (83)
(4.1) 15.6 (3.7) 16.3 (5.2)
25.4 8.4–24.7 6.6–35.0
18.3 13–17.2 13.5–17.6
ratio; SD, standard deviation.
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characteristics were similar at baseline between the groups
(Table 1). The mean daily dose of UDCA at study entry was
15.6–16.3 mg/kg across all treatment groups (recommended
dosing range 13–15 mg/kg/d). Most patients (82%)
completed the study; pruritus was the principal reason for
discontinuation (10%). The mITT population of 161 patients
was evaluated for the primary end point.Primary Efﬁcacy End Point
The primary end point in the study, relative (percent)
change in mean ALP levels in the mITT group from day 0 to
day 85 compared with placebo, was met across all OCA
dose groups with statistical signiﬁcance (P < .0001,
Figure 1A). Speciﬁcally, mean relative change in ALP from
baseline from day 0 to day 85 was a decrease of 24% (95%
conﬁdence interval [CI]: 30% to 18%), 25% (95%
CI: 30% to 20%), and 21% (95% CI: 30% to 12%)Figure 1. (A) Mean ± SD ALP relative change from baseline to
end of study in the mITT (last observation carried forward)
population. P < .0001 pair-wise comparison for all treatment
groups. (B) Percent decrease in ALP values in the completer
population. Pairwise comparisons for 10%, 20% and 40%
cutoff, respectively: 10 mg P < .0001, P < .0001, P ¼ .0031;
25 mg P < .0001, P < .0001, P ¼ .0272; 50 mg P < .000l for
all cutoffs, respectively. P value: Comparison of proportion of
patients with a 10%, 20%, 40%, or complete response for
OCA dose groups with placebo group using the likelihood
ratio c2 test. **P < .05; ***P < .0001.for the 10 mg, 25 mg, and 50 mg OCA groups, respectively,
compared with a 3% decrease in the placebo group (95%
CI: 7% to 2%) (Figure 1A). The results were virtually
identical when the primary end point was applied to the
ITT and completer populations (P < .0001 for all OCA
doses). The maximum decreases in ALP values in the
completer population (Figure 2A and B) occurred on day 85
(3 months) for all OCA dose groups. However, statistically
signiﬁcant ALP reductions were observed as early as the
2-week study visit, and the vast majority of the effect was
seen at 1 month.
Alkaline Phosphatase Completer Analysis
There were also statistically signiﬁcant ALP reductions
of 10%, 20%, and 40% in patients completing therapy in all
OCA groups vs placebo (Figure 1B). Speciﬁcally, 87% (86 of
99) of OCA-treated patients completing therapy achieved at
least a 10% ALP reduction, compared with 14% of placebo
patients (5 of 37). Similarly, 69% (68 of 99) of OCA-treated
patients showed at least a 20% reduction in ALP compared
with 8% (3 of 37) of placebo-treated patients. ALP
normalization was only achieved in 7% (7 of 99) of OCA-
treated patients, but in no placebo patients.
Efﬁcacy Assessed by Published
Response Criteria
The efﬁcacy of OCA was also evaluated using 5 major
published PBC biochemical algorithms that describe criteria
shown to be predictive of adverse clinical outcomes (liver
transplant or death): Paris I,8 Paris II,9 Toronto I,25 Toronto
II,26 and Mayo II.27 Although these criteria differ in their
deﬁnition of biochemical response with respect to the key
liver enzymes assessed and their threshold levels, all algo-
rithms include an ALP criterion, the level of which varies
(range, 1.5–3 ULN). Some algorithms employ other liver
tests, such as bilirubin (1 mg/dL) or AST (1.5–2
ULN).8,9 Regardless of the algorithm used, OCA-treated pa-
tients always had higher rates of response than placebo-
treated patients (Table 2).
ALP Assessment of Open-Label
Extension Therapy
After the double-blind portion of the study, 78 patients
at select centers were enrolled into an open-label extension
study. The biochemical results at 3, 6, 9, and 12 months are
presented (Figure 2C and D, Supplementary Figure 2). The
biochemical improvements observed in the 3-month double-
blind phase were maintained during the open-label exten-
sion (12 months or more) (Supplemental Figure 3). Mean
ALP for all 3 cohorts after 3 months in the open-label
extension was 210 ± 12 U/L and after 12 months had
further decreased to 202 ± 11 U/L.
Secondary End Points
Other liver biochemistry. Signiﬁcant reductions in
values of GGT (48% to 63%) and ALT (21% to 35%) were
observed for all OCA treatment groups compared with
Figure 2.OCA treatment decreases serum ALP levels in patients with PBC in the double-blind (DB) trial and the open-label
extension. (A) Decreases in ALP values during the DB phase were signiﬁcant for all OCA dose groups vs placebo at all the
study day visits (P < .0001). After OCA withdrawal on day 85, mean ALP values started to increase, but 2 weeks later had not
reached mean baseline ALP values and remained statistically lower compared with the placebo group. ALP values in the
completer population in the DB trial. P < .0001 for all OCA dose groups vs placebo. (B) Change in ALP values in the completer
population in the DB trial. P < .0001 for all OCA dose groups vs placebo. (C) Decreases in ALP values during the open-label
extension trial were signiﬁcant for all OCA dose groups vs placebo at all the study day visits (P < .0001). (D) Change in ALP
values during the open-label extension trial for the completer population. P < .0001 for all OCA dose groups vs placebo at all
the study day visits. *P < .01; **P < .001; ***P < .0001.
April 2015 OCA Treatment of PBC 755
CL
IN
IC
AL
LI
VE
Rplacebo from baseline to end of treatment (Table 3).
Placebo-treated patients experienced essentially no change
in these analytes from baseline to day 85. OCA was also
associated with signiﬁcant reductions in AST values (9% to
17%) for all dose groups compared with placebo. Although
mean conjugated bilirubin levels were in the normal range
in all treatment groups at baseline, reductions in the median
values were seen in the OCA treatment groups compared
with a small increase in the placebo group (Table 3).
Inﬂammatory markers. C-reactive protein and IgM
values also showed signiﬁcant reductions from baseline at
the end of the study with OCA treatment. Median C-reactive
protein values decreased 21%, 42%, and 33% (P ¼ .0595
for 10 mg; P ¼ .0009 for 25 mg, and not signiﬁcant for 50
mg compared with baseline values) in all 3 OCA treatment
groups in comparison with a 10% increase for placebo.
Median IgM values decreased by 14%, 21%, and 18% at10 mg, 25 mg, and 50 mg OCA (P ¼ .0003 for 10 mg;
P < .0001 for 25 and 50 mg compared with baseline),
respectively, vs a 19% increase in the placebo group.
Fibroblast growth factor 19, bile acid precursor
C4 (7a-hydroxy-4-cholesten-3-one), and endogenous
bile acids levels analysis. Consistent with FXR agonist
effects, signiﬁcant increases in FGF19 from baseline to end
of treatment were observed for 10-mg and 25-mg OCA dose
groups compared with placebo (Figure 3A). Signiﬁcant re-
ductions in C4 (Figure 3B) and total endogenous BAs
(Figure 3C) were observed in all OCA dose groups
compared with an increase in the placebo group. Endoge-
nous BA (ie, BAs excluding UDCA and OCA) showed a sig-
niﬁcant dose-related decrease compared with placebo.
Mean values and SD of the individual and total BAs
measured at baseline and at the end of the study (UDCA,
CDCA, cholic acid, lithocholic acid, DCA, and OCA) are
Table 2.Biochemical Treatment Response Criteria: Baseline and Day 85 Response
Treatment groups/criterion
Placebo
(n ¼ 38)
OCA, 10 mg
(n ¼ 38)
OCA, 25 mg
(n ¼ 48)
OCA, 50 mg
(n ¼ 41)
ALP 3 ULN and AST 2 ULN and tBili 1 mg/dLa
Baseline (biochemical nonresponse), n 5 11 10 10
Day 85 (biochemical nonresponse), n 5 7 3 5
Day 85 Baseline nonresponders with treatment effect, % 0 36 70 50
P value .2445 .0256 .1009
ALP 1.5 ULN and AST 1.5 ULN and tBili 1 mg/dLb
Baseline (biochemical nonresponse), n 34 34 46 40
Day 85 (biochemical nonresponse), n 30 22 30 25
Day 85 baseline nonresponders with treatment effect, % 12 35 35 35
P value .0433 .0210 .0280
ALP 1.67 ULNc
Baseline (biochemical nonresponse), n 32 30 39 35
Day 85 (biochemical nonresponse), n 28 17 22 19
Day 85 baseline nonresponders with treatment effect, % 13 43 44 43
P value .0099 .0047 .0063
ALP 1.76 ULNd
Baseline (biochemical nonresponse), n 29 28 38 30
Day 85 (biochemical nonresponse), n 24 17 20 14
Day 85 baseline nonresponders with treatment effect, % 17 39 47 50
P value .0819 .0184 .0119
ALP 1.67 ULN and tBili 1 mg/dLe
Baseline (biochemical nonresponse), n 33 30 39 37
Day 85 (biochemical nonresponse), n 28 18 22 21
Day 85 baseline nonresponders with treatment effect, % 15 40 44 41
P value .0452 .0110 .0185
ALP 1.67 ULN and tBili ULNf
Baseline (biochemical nonresponse), n 21 22 30 25
Day 85 (biochemical nonresponse), n 19 17 18 17
Day 85 baseline nonresponders with treatment effect, % 10 23 40 28
P value .4121 .0248 .1430
NOTE. Bold type indicates signiﬁcant values. Treatment groups were compared using Fisher exact test.
tBili, total bilirubin.
The evaluation of the treatment groups for various published algorithm (aParis I; bParis II; cToronto I; dToronto II) and
e,fdeviations of Toronto I with the incorporation of normal bilirubin levels.
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centrations were similar for placebo and OCA-treated pa-
tients (Supplementary Table 4). The majority of total
baseline BA concentration (63%–65%) was UDCA (consis-
tent with the mean 16 mg/kg dose being taken by the pa-
tients), followed by CDCA (11%–15%), cholic acid (11%–
12%), and DCA (5%–7%). Lithocholic acid composed <1%
of total BA concentrations. In treated patients, OCA consti-
tuted <2% of total plasma BAs.Adverse Events
Overall, 84% (32 of 38) of the placebo-treated and 96%
(122 of 127) of OCA-treated patients experienced at least
one AE (Supplementary Tables 5 and 6). Apart from pruri-
tus, only mild or moderate nausea was reported more
frequently in all 3 OCA groups than in the placebo group.
Severe AEs were primarily due to pruritus, and of 37, 30
patients with severe AEs were pruritus related.
Pruritus. Although pruritus was no more common in
the OCA 10-mg group compared with the placebo group, the
severity appeared to be worse at this dose, and both theincidence and severity were worse in the 2 higher-dosing
groups. The incidence of pruritus in the OCA 10-mg, 25-mg,
and 50-mg groups were 47% (not signiﬁcant), 85%
(P< .0003), and 80% (P< .006) vs 50% in the placebo group
(Figure 4A, Supplementary Table 6). Severe pruritus was
reported in 16% (6 of 38) of the patients in the 10-mg group,
24% (9 of 37) of the patients in the 25-mg group, and 37%
(15 of 41) of the patients in the 50-mg group of patients,
respectively. Overall, severe pruritus was less commonly
reported during the open-label extension trial (Figure 4B)
and although 87% (68 of 78) of patients experienced some
pruritus, only 13% (10 of 78) discontinued OCA treatment as
a result (Supplementary Table 7).
Lipid changes. Across all treatment groups, patients at
baseline had elevated levels of total cholesterol (median,
218–239 mg/dL), low-density lipoprotein cholesterol (me-
dian, 123–133 mg/dL), and high-density lipoprotein (HDL)
cholesterol (median, 65–70 mg/dL), and normal to low
levels of triglycerides (median, 113–119 mg/dL). A dose-
related decrease in total cholesterol of 3%, 5%, and 13%
was noted for OCA 10-mg, 25-mg, and 50-mg groups,
respectively, mediated by a decrease in HDL levels (Table 3
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Figure 3.OCA treatment increases FGF19 and decreases C4
and endogenous BA plasma levels. Increased FGF19 (A),
associated with decreased C4 (B), and endogenous BA (C)
plasma levels in PBC patients after OCA treatment. Data are
presented as median (line in middle of box), interquartile
range (top and bottom of box), minimum and maximum
(outliers denoted by diamonds). Statistical signiﬁcance is
based on the change from baseline to end of treatment. After
treatments with 10 mg, 25 mg, and 50 mg OCA, changes in
FGF19 levels (P ¼ .0007; P < .0001; P ¼ .002), C4 (P ¼ .0275;
P < .0001; P < .0003), and BA (P ¼ .0093; P < .0001;
P < .0001) were all respectively signiﬁcant.
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were not meaningfully changed. HDL levels remained stable
after the early decline at each follow-up visit in OCA treated
subjects.
Other adverse events. Seven patients (4%; 7 of 165)
experienced a serious AE during the study, including one
Figure 4. Pruritus severity in PBC patients expressed as percent of patients with mild, moderate, or severe pruritus. (A) Pruritus
severity in the double-blind phase. (B) Pruritus severity in the open-label OCA therapy extension.
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LIVERpatient in the placebo arm (dyspnea) and one patient in the
OCA 25-mg arm (resection of nonmalignant, pre-existent
Warthin salivary gland tumor). Five patients in the OCA
50-mg group had 6 serious AEs; 3 had nonhepatic
AEs (presumed gastroesophageal reﬂux disease and
angioedema/angina pectoris due to a food allergy that did
not reoccur with continuing OCA treatment) and 3 patients
had gastrointestinal/hepatic AEs. One patient developed an
upper gastrointestinal esophageal bleed approximately 1
week after therapy for pre-existing esophageal varices (that
was not revealed to the investigator), 2 patients had sig-
niﬁcant increases in their bilirubin and aminotransferase
levels that reverted to prestudy levels after OCA therapy
was discontinued. OCA was restarted in one of these pa-
tients without an additional rise in her bilirubin or amino-
transferases. In total, 27 patients discontinued the study:
23 patients due to an AE, 3 patients with elevated conju-
gated bilirubin, 1 patient with elevated AST/ALT; the ma-
jority of these patients (56%; 15 of 27) were receiving OCA
at the highest dose of 50 mg (Supplementary Table 5).
Open-label extension over 1 year. Seventy-eight
patients were enrolled in the open-label protocol after
completion of the double-blind trial; 61 patients (78%; 61 of
78) completed 1 year of dosing. Nearly all patients were
restarted at a mean daily OCA dose of 10 mg (75 patients
[96%; 75 of 78]), and patients were allowed to titrate OCA
dosing at the discretion of the treating physician based on
ALP response and tolerability. OCA daily doses ranged from
3 mg to 60 mg daily throughout the trial. The mean ﬁnal
daily dose at 12 months was 20 mg. Although most patients
(87%) reported some pruritus during the open-label phase
of the trial, the pruritus was generally less severe than in the
double-blind phase (Figure 4). Nineteen patients (24%; 19
of 78) discontinued the open-label extension trial: pruritus
(13%; 10 of 78); other AEs (5%; 4/78; sleep–wake schedule
disorder, rising blood glucose, left eye vitreous detachment,
elevated conjugated bilirubin); consent withdrawal (3%, 2
of 78); major protocol violation (1%; 1 of 78); and other
reasons (3%; 2 of 78) (see Supplementary Tables 7 and 8
for patient disposition and incidence of adverse events).Discussion
This international, multicenter, placebo-controlled trial
evaluated the utility of OCA across a range of doses for the
treatment of PBC in patients with inadequate response to
UDCA. OCA produced signiﬁcant decreases in 2 biochemical,
surrogate markers of PBC outcomes, ALP and bilirubin. In
addition, OCA may improve underlying immunologic and
inﬂammatory processes at play in PBC, as both C-reactive
protein and IgM (the hallmark elevated immunoglobin in
PBC) were signiﬁcantly reduced. Pruritus, the most common
symptom in PBC, was exacerbated with OCA treatment in a
dose-related manner.
The study data strongly suggest OCA primarily mediates
its effects in PBC via FXR agonism. Physiologically, a BA with
FXR agonist properties would be expected to induce FGF19
production from gut enterocytes, which would, in turn,
mediate (via induction of the nuclear receptor small heter-
odimer partner [SHP]) a decrease in endogenous BA syn-
thesis, the postprandial signal to decrease BA synthesis.31
Such effects were conﬁrmed in this clinical study: serum
FGF19 concentrations increased in a dose-related manner
and both C4 (a BA precursor) and endogenous BA concen-
trations decreased. In contrast, UDCA is not an FXR
agonist,32 and is thought to mediate its beneﬁcial effects in
PBC by several mechanisms, including diluting toxic BAs
and promoting their excretion, providing biliary tract pro-
tection by up-regulating the biliary bicarbonate “umbrella”,
and exerting immune-modulatory and anti-inﬂammatory
effects.33–35 UDCA has low detergent properties requiring
administration of large doses (13–15 mg/kg/d) to be
effective in PBC. Consequently, UDCA becomes the pre-
dominant BA comprising >60% of the BA pool. In contrast
OCA, which comprised <2% of the serum BAs at the end of
this study, appears to exert its effects at approximately 100-
fold lower doses than UDCA. Considered together, these
complementary mechanisms likely explain the signiﬁcant
additional efﬁcacy seen when OCA was added to UDCA in
this study. OCA monotherapy efﬁcacy in patients with PBC
has been documented in a separate study,36 supporting the
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UDCA dosing (ClinicalTrials.gov ID: NCT00570765).
With the use of UDCA for the treatment of PBC, the
prognostic utility of ALP and other biochemical markers as
surrogates for the “hard” end points of death and liver
transplantation continues to be evaluated.8–10 Recently, 2
groups analyzing large PBC cohorts have shown that lower
ALP alone and combined with other biochemical markers is
associated with better transplant-free survival, both when
assessed at discrete thresholds11 and as a continual vari-
able.37 Our study shows that OCA produces signiﬁcant
reductions in ALP, GGT, and, to a lesser extent, the amino-
transferases. Bilirubin, which has long been shown to be
predictive of clinical outcomes in PBC,38 decreased signiﬁ-
cantly in 2 of the OCA groups in the trial, even though the
vast majority of patients had mean bilirubin levels within
the normal range.
No clear differences were observed in biochemical end
points across the 5-fold range of OCA doses studied,
strongly suggesting that the dose range studied in this trial
was too high. This ﬁnding is somewhat surprising, based on
preclinical rodent studies that have consistently shown
doses of 5–30 mg/kg are needed to elicit a therapeutic
response in appropriate models.21 The 10-mg dose of OCA
represents approximately a 0.14-mg/kg dose in patients
with PBC—nearly 10 times lower than the effective doses in
the animal studies. A likely explanation for these interspe-
cies differences is that CDCA (on which OCA is based) is the
natural FXR ligand in man, but is not in rodents.
Pruritus was by far the most common AE in the study
and was clearly OCA dose-related. Although the exact me-
diators of cholestatic pruritus remain to be elucidated, 2
mechanisms have been proposed: activation of the autotaxin
pathway39 and activation of TGR5.40–42 Data from the cur-
rent study are inconsistent with TGR5-induced pruritus;
OCA is a weak TGR5 agonist and actually reduced levels of
the endogenous human TGR5 agonist, DCA. Whether OCA
activates the autotaxin pathway has yet to be determined.
The incidence of pruritus in the 10-mg OCA group was no
higher than that seen in the placebo patients (although
the pruritus was more severe). Based on the dose-response
related pruritus observed in this study, we believe that
doses of OCA <10 mg will be better tolerated. A Phase 3
study of OCA is designed to address this issue
(ClinicalTrials.gov ID: NCT01473524).
PBC patients with early disease have elevated HDL
levels, however, altered risks of cardiovascular morbidity
relative to the general population have not been clearly
demonstrated.10,43 In this study, OCA treatment was asso-
ciated with decreases in total and HDL cholesterol. Adverse
cardiovascular events are unlikely to be a concern during
the 3-month double-blind or open-label extension, however,
longer studies are ongoing to explore potential adverse ef-
fects of chronic FXR activation, particularly on lipid ho-
meostasis (ClinicalTrials.gov ID: NCT01865812).
The mechanism by which OCA contributes to lowering
HDL has not been established in humans, but the observa-
tion is consistent with the OCA-mediated effects of FXR in
animals and could be related to up-regulation of reversecholesterol transport through SR-B1 activation. Speciﬁcally,
FXR knockout mice display hypercholesterolemia due to a
marked increase in HDL driven by down-regulation of SR-
B1, a key receptor for hepatic clearance of cholesterol
from HDL.44 Similarly, partial or complete knockout of SR-
B1 results in elevations in HDL with marked increases in
mature, lipid-rich HDL.45 OCA has been shown in animal
models to lower HDL driven by a decrease in mature, lipid-
rich HDL.46 In addition, atherogenic plaque formation was
reduced by OCA in proatherogenic mice and led to a selec-
tive reduction of HDL2c or ApoAI in cynomolgus mon-
keys.46,47 Nonetheless, the potential cardiovascular
implication of these effects in humans needs to be estab-
lished. Future studies will evaluate lipid proﬁles in patients
with PBC to delineate HDL particle formation, maturation,
and clearance, as well as macrophage cholesterol efﬂux
before and after treatment with OCA (ClinicalTrials.gov ID:
NCT01865812).
Limitations of the trial include limited duration of the
study, the dose range evaluated and the need for additional
mechanistic studies focusing on pruritus and the lipid pro-
ﬁle. Although biochemical surrogates are of clear value in
PBC,8,9,25–27,37 we acknowledge the challenges of applying
any surrogate end point in the development and approval of
new drugs.
In conclusion, we present randomized controlled clin-
ical trial data demonstrating biochemical efﬁcacy of OCA, a
FXR agonist, when given to patients with PBC with an
inadequate response to UDCA therapy. Across all doses
tested, biochemical efﬁcacy of OCA was evident; based on
the balance of efﬁcacy and tolerability, in this study 10-mg
once daily dose of OCA was the most effective dose, and
has formed the basis for additional studies of OCA in PBC.
Evaluating the lower end of the dose–response relation-
ship in treatment of PBC is merited, as is a strategy of
titrating the dose of OCA based on an evaluation that in-
cludes biochemical markers and symptomatic response to
low doses of the drug. Our trial, therefore, supports
ongoing efforts to further evaluate the long-term safety
and clinical efﬁcacy of OCA as a new therapy for patients
with PBC.Supplementary Material
Note: To access the supplementary material accompanying
this article, visit the online version of Gastroenterology at
www.gastrojournal.org, and at http://dx.doi.org/10.1053/
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Supplementary Figure 1. Patient disposition.
Supplementary Figure 2. Dose-titration effect of OCA therapy in the open-label extension. Panel A compares the effect of
OCA at 10 mg and 25 mg daily; panel B compares the effect of OCA at 25 mg and 50 mg daily. ALP values are presented as
mean ± SD percent change from baseline after a 30-day pre-titration (gray bars) and 30-day post-titration (black bars) dosing.
**P ¼ .01 for relative change from baseline compared with placebo.
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Supplementary Figure 4.Mean absolute levels of (A) low-
density lipoprotein (LDL) and (B) high-density lipoprotein
(HDL) and over time. Data are mean values for safety
population.
Supplementary Figure 3. Safety population. Persistent
biochemical response in PBC patients after OCA therapy in
the open-label extension. Patients on OCA therapy in the OLE
demonstrated sustained reduction compared with baseline in
GGT (A), ALT (B), and AST (C) levels 1 year after treatment
initiation. ** P < .001 and *** P < .0001 (transaminases and
GGT, all time points) vs time 0. Data are mean ± SD.
761.e3 Hirschﬁeld et al Gastroenterology Vol. 148, No. 4
Supplementary Table 1.Study Power Calculations
Assumed numbersa (for sample size calculation)
Observed numbersb
10 mg 25 mg 50 mg
Meanplacebo, % 1 3.5 6 2.6 2.6 2.6
Meanactive, % 8 13 20 23.7 24.7 21.0
Difference (meanplacebo – meanactive), % 7 10.5 14 21.1 22.1 18.4
SD, % 10 15 20 15.4c 15.8c 21.6c
Effect size 0.7 0.7 0.7 1.37 1.40 0.85
Power, % 80 80 80 99 99 95
n (per group) 35 35 35 37d 42d 38d
NOTE. The difference of means and standard deviation (SD) are to be set for the estimation of the effect size, which is
calculated as (meanactive  meanplacebo)/SD. The listed mean values are examples that could result in the speciﬁed difference
of means.
aLeading to an effect size of 0.7.
bmITT; percent change from baseline.
cCommon SD calculated using observed SDs from treatment groups.
dMean number of observed patients in both treatment groups.
Supplementary Table 2.Missing Data From the Double-Blind Trial
No. of subjects analysis by time point for:
Treatment group
Total
(n ¼ 165), n (%)
Placebo
(n ¼ 38)
OCA 10 mg
(n ¼ 38)
OCA 25 mg
(n ¼ 48)
OCA 50 mg
(n ¼ 41)
ALP, ALT, AST, GGT, conjugated bilirubin,
cholesterol, LDL, HDL, and TG
Baseline 38 38 48 41 165
Day 15 36 38 46 33 153 (93)
Day 29 37 35 43 27 142 (86)
Day 57 36 33 41 26 136 (82)
Day 85/ET 38 38 48 40 164 (99)
Day 99 38 35 43 34 150 (91)
CRP
Baseline 32 36 41 35
Day 85/ET 31 28 36 30
Change from baseline, n (%) 28 (74) 28 (74) 31 (65) 27 (66)
IgM
Baseline 32 35 41 35
Day 85/ET 33 29 38 31
Change from baseline, n (%) 30 (79) 28 (74) 33 (69) 28 (68)
FGF19/Total BA
Baseline 32 32 42 34
Day 85/ET 35 29 40 33
Change from baseline, n (%) 30 (79) 26 (68) 38 (79) 30 (73)
CRP, C-reactive protein; ET, end of therapy; LDL, low-density lipoprotein; TG, triglyceride.
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Supplementary Table 3.Bile Acid Levels at Baseline and Month 3 in the Intent-to-Treat Population During the Double-Blind
Trial
BA analytes
Treatment group
Placebo
(n ¼ 32)
OCA, 10 mg
(n ¼ 32)
OCA, 25 mg
(n ¼ 42)
OCA, 50 mg
(n ¼ 34)
Total BA, mmol/L
Baseline, mean (SD) 18.8 (24.3) 33.9 (27.0) 28.4 (30.5) 37.8 (56.2)
Month 3, mean (SD) 23.2 (25.5) 30.6 (42.9) 24.1 (35.8) 72.6 (142.2)
Mean (SD) change from baseline to month 3 0.53 (19.2) -4.5 (34.3) -3.0 (29.9) 33.5 (153.2)
Median change from baseline to month 3 1.27 5.95 4.36 4.17
P valuesa NA .1549 .1946 .2903
Total UDCA, mmol/L
Baseline, mean (SD) 12.4 (15.6) 22.9 (20.0) 18.4 (19.9) 21.8 (30.7)
Month 3, mean (SD) 14.4 (15.0) 20.8 (31.5) 17.8 (21.9) 47.2 (87.8)
Mean (SD) change from baseline to month 3 0.08 (12.9) 2.32 (27.6) 0.07 (20.4) 24.0 (98.6)
Median change from baseline to month 3 0.72 2.55 0.23 1.96
P valuesa NA .2381 .7662 .6408
Total CDCA, mmol/L
Baseline, mean (SD) 2.40 (3.75) 4.71 (4.13) 4.22 (5.46) 7.21 (14.65)
Month 3, mean (SD) 3.53 (4.51) 4.96 (7.67) 2.54 (5.15) 15.81 (37.95)
Mean (SD) change from baseline to month 3 0.34 (3.20) 0.13 (4.62) -1.35 (4.09) 9.01 (37.01)
Median change from baseline to month 3 0.194 0.736 0.564 0.898
P valuesa NA .0542 .0005 .0189
Total CA, mmol/L
Baseline, mean (SD) 2.46 (3.64) 4.20 (4.30) 3.91 (5.87) 6.21 (11.96)
Month 3, mean (SD) 3.46 (5.34) 3.13 (6.18) 2.88 (10.80) 6.54 (16.31)
Mean (SD) change from baseline to month 3 0.45 (3.26) 1.70 (4.66) 0.79 (8.24) 0.26 (17.23)
Median change from baseline to month 3 0.04 0.68 1.09 1.00
P valuesa NA .0030 .0003 .0044
Total DCA, mmol/L
Baseline, mean (SD) 1.27 (2.35) 1.81 (1.76) 1.65 (2.07) 2.33 (2.59)
Month 3, mean (SD) 1.60 (1.99) 1.10 (2.44) 0.36 (0.71) 1.28 (2.99)
Mean (SD) change from baseline to month 3 0.13 (1.70) 0.87 (1.98) 1.16 (1.66) 1.25 (4.22)
Median change from baseline to month 3 0.000 0.31 0.64 1.02
P valuesa NA .0021 <.0001 <.0001
Total LCA, mmol/L
Baseline, mean (SD) 0.194 (0.320) 0.282 (0.363) 0.227 (0.398) 0.305 (0.445)
Month 3, mean (SD) 0.196 (0.291) 0.321 (0.492) 0.167 (0.226) 0.305 (0.396)
Mean (SD) change from baseline to month 3 0.034 (0.185) 0.001 (0.326) 0.030 (0.222) 0.055 (0.529)
Median change from baseline to month 3 0.000 0.000 0.021 0.000
P valuesa NA .3782 .3245 .6839
Total endogenous bile acids, mmol/L
Baseline, mean (SD) 6.35 (9.54) 11.0 (9.07) 10.0 (12.9) 16.0 (28.3)
Month 3, mean (SD) 8.80 (11.6) 9.52 (14.9) 5.95 (15.6) 23.9 (54.4)
Mean (SD) change from baseline to month 3 0.6 (7.6) 2.4 (9.8) 3.3 (12.0) 8.0 (54.4)
Median change from baseline to month 3 0.0 2.3 3.1 3.7
P valuesa NA .0108 .0001 .0071
Total OCA, mmol/L
Baseline, mean (SD) 0.000 0.000 0.000 0.003 (0.018)
Month 3, mean (SD) 0.000 0.252 (0.410) 0.371 (0.525) 1.552 (5.202)
NA, not applicable; SD, standard deviation.
aP values: Comparison of OCA dose group with placebo group using Wilcoxon Mann-Whitney test.
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Supplementary Table 4.Mean Relative Proportion of Individual Bile Acids to Total Bile Acid Concentration at Baseline and
Month 3 in the Intent-to-Treat Population During the Double-Blind Trial
Laboratory analytes
Treatment group
Placebo (n ¼ 38) OCA, 10 mg (n ¼ 38) OCA, 25 mg (n ¼ 48) OCA 50 mg (n ¼ 41)
Total UDCA
Baseline 0.654 0.632 0.641 0.630
Month 3 0.634 0.685 0.794 0.752
Total CDCA
Baseline 0.106 0.145 0.121 0.144
Month 3 0.133 0.140 0.069 0.092
Total CA
Baseline 0.118 0.115 0.109 0.119
Month 3 0.112 0.070 0.051 0.056
Total DCA
Baseline 0.051 0.051 0.069 0.051
Month 3 0.063 0.019 0.003 0.009
Total LCA
Baseline 0.000 0.000 0.004 0.000
Month 3 0.003 0.000 0.002 0.009
Total OCA
Month 3 NA 0.014 0.013 0.018
NOTE. Values are mean relative proportion.
NA, not applicable.
Supplementary Table 5.Summary of Treatment-Emergent Adverse Events by Treatment Group in the Double-Blind Trial
Treatment group
Total
(n ¼ 165)
Placebo
(n ¼ 38)
OCA, 10 mg
(n ¼ 38)
OCA, 25 mg
(n ¼ 48)
OCA, 50 mg
(n ¼ 41)
Subjects with any AEs, n (%) 32 (84) 34 (89) 47 (98) 41 (100) 154 (93)
Subjects with treatment-related AE,a n (%) 22 (58) 28 (74) 45 (94) 38 (93) 133 (81)
Subjects with serious AE, n (%) 1 (3) 0 (0) 1 (2) 5 (12) 7 (4)
Subject deaths, n (%) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Subjects who withdrew due to an AE,b n (%) 1 (3) 5 (13) 5 (10) 12 (29) 23 (14)
AE reports (entries), n 96 101 152 198 547
Mild 68 58 91 96 313
Moderate 21 35 50 76 182
Severe 7 8 11 26 52
aRelated adverse events include “possibly” or “probably” relationship.
bThree additional subjects discontinued the study due to elevated conjugated bilirubin.
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Supplementary Table 6. Incidence of All Adverse Events Occurring in 5% in Any Treatment Group During the Double-Blind
Trial
System organ class/preferred term
Treatment group
Placebo
(n ¼ 38)
OCA, 10 mg
(n ¼ 38)
OCA, 25 mg
(n ¼ 48)
OCA, 50 mg
(n ¼ 41)
Subjects with any AEs 32 (84) 34 (89) 47 (98) 41 (100)
Skin and subcutaneous tissue disorders 21 (55) 19 (50) 43 (90) 36 (88)
Pruritus 19 (50) 18 (47) 41 (85) 33 (80)
Rash 0 (0) 0 (0) 1 (2) 2 (5)
Gastrointestinal disorders 10 (26) 17 (45) 17 (35) 17 (41)
Abdominal distension 1 (3) 2 (5) 0 (0) 4 (10)
Abdominal pain 2 (5) 1 (3) 2 (4) 2 (5)
Abdominal pain upper 1 (3) 0 (0) 2 (4) 2 (5)
Constipation 3 (8) 3 (8) 4 (8) 3 (7)
Diarrhea 3 (8) 3 (8) 4 (8) 3 (7)
Dyspepsia 0 (0) 2 (5) 2 (4) 2 (5)
Nausea 1 (3) 4 (11) 3 (6) 4 (10)
Vomiting 0 (0) 0 (0) 3 (6) 0 (0)
General disorders and administration site
conditions
7 (18) 9 (24) 8 (17) 10 (24)
Chest pain 0 (0) 0 (0) 0 (0) 2 (5)
Chills 0 (0) 0 (0) 2 (4) 2 (5)
Fatigue 5 (13) 7 (18) 3 (6) 5 (12)
Edema peripheral 0 (0) 1 (3) 1 (2) 2 (5)
Pyrexia 0 (0) 3 (8) 0 (0) 0 (0)
Infections and infestations 10 (26) 8 (21) 5 (10) 11 (27)
Bronchitis 0 (0) 2 (5) 0 (0) 0 (0)
Gastroenteritis viral 0 (0) 0 (0) 0 (0) 2 (5)
Nasopharyngitis 1 (3) 2 (5) 1 (2) 0 (0)
Sinusitis 2 (5) 1 (3) 0 (0) 2 (5)
Tooth abscess 0 (0) 2 (5) 0 (0) 1 (2)
Upper respiratory tract infection 2 (5) 0 (0) 1 (2) 0 (0)
Urinary tract infection 3 (8) 0 (0) 0 (0) 0 (0)
Nervous system disorders 4 (11) 4 (11) 9 (19) 8 (20)
Headache 4 (11) 3 (8) 5 (10) 7 (17)
Hyperesthesia 0 (0) 0 (0) 0 (0) 2 (5)
Respiratory, thoracic and mediastinal disorders 6 (16) 3 (8) 4 (8) 11 (27)
Cough 1 (3) 1 (3) 0 (0) 2 (5)
Dyspnea 2 (5) 0 (0) 0 (0) 0 (0)
Oropharyngeal pain 1 (3) 2 (5) 4 (8) 0 (0)
Epistaxis 0 (0) 0 (0) 0 (0) 4 (10)
Musculoskeletal and connective tissue disorders 5 (13) 5 (13) 3 (6) 6 (15)
Arthralgia 1 (3) 2 (5) 2 (4) 0 (0)
Myalgia 2 (5) 1 (3) 0 (0) 0 (0)
Pain in extremity 0 (0) 0 (0) 1 (2) 4 (10)
Investigations 3 (8) 3 (8) 2 (4) 2 (5)
Metabolism and nutrition disorders 1 (3) 3 (8) 1 (2) 4 (10)
Hypokalemia 0 (0) 0 (0) 0 (0) 2 (5)
Psychiatric disorders 1 (3) 3 (8) 3 (6) 2 (5)
Insomnia 0 (0) 2 (5) 1 (2) 2 (5)
Ear and labyrinth disorders 2 (5) 1 (3) 3 (6) 2 (5)
Vertigo 2 (5) 0 (0) 0 (0) 0 (0)
Eye disorders 1 (3) 0 (0) 4 (8) 3 (7)
Dry eye 1 (3) 0 (0) 3 (6) 2 (5)
Injury, poisoning and procedural complications 1 (3) 1 (3) 1 (2) 2 (5)
Contusion 1 (3) 0 (0) 0 (0) 2 (5)
Hepatobiliary disorders 0 (0) 0 (0) 0 (0) 4 (10)
Renal and urinary disorders 1 (3) 2 (5) 1 (2) 0 (0)
Reproductive system and breast disorders 2 (5) 1 (3) 1 (2) 0 (0)
Cardiac disorders 2 (5) 0 (0) 0 (0) 1 (2)
Palpitations 2 (5) 0 (0) 0 (0) 0 (0)
NOTE. Values are n (%).
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Supplementary Table 7.Patient Disposition in the
Open-label Extension Trial
Reason for discontinuation Patients (n ¼ 78)
Pruritus 10 (13)
Other adverse event 3 (4)
Increased conjugated bilirubin 1 (1)
Protocol violation 1 (1)
Withdrew consent/lost 2 (3)
Other 2 (3)
NOTE. Values are n (%).
Supplementary Table 8. Incidence of All Adverse Events
Occurring in 5% in Any Treatment
Group in the Open-Label Extension
Trial
Adverse event Patients (n ¼ 78)
Pruritus 68 (87)
Fatigue 10 (13)
Insomnia 10 (13)
Upper respiratory tract infection 10 (13)
Headache 8 (10)
Rash 8 (10)
Constipation 7 (9)
Abdominal distension 6 (8)
Nausea 4 (5)
Edema peripheral 5 (6)
Nasopharyngitis 7 (9)
Sinusitis 5 (6)
Excoriation 6 (8)
Arthralgia 5 (6)
Pain in extremity 5 (6)
Nasal congestion 4 (5)
Ecchymosis 5 (6)
NOTE. Values are n (%).
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